By modulating NNMT activity, this compound has been studied in research contexts for its effects on metabolic pathways and cellular NAD+ availability
Its generally safe for diabetics but its side effects and variable effectiveness in non-diabetics mean proceed with caution
The reasoning that follows extrapolates from dog, monkey and rat, and species extrapolation of clearance is an inference, not a demonstration
Read more ) Lixisenatide: Initial results from a proof-of-concept phase 2 trial conducted in France are expected this year
The ACC document, which was endorsed by the American Diabetes Association (ADA), outlined a variety of considerations for use of these agents in patients with ASCVD, including considerations that may warrant selection of either a GLP-1 RA or an SGLT-2 inhibitor for cardiovascular risk reduction ( Table 1 )
GLP1 is a gut hormone released after eating that helps regulate appetite by signaling fullness to the brain, slowing stomach emptying, and enhancing satiety